

<b>Reference:</b>	FOI.8467.22
<b>Subject:</b>	Patient treatments
<b>Date of Request:</b>	14 March 2022

**Requested:**

1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):
  - Cutaquig
  - Cuvitru
  - Gammanorm
  - Hizentra
  - Hyqvia
  - Subgam
  - Privigen
  - Octagam
  - Intratect
  - Gamunex
  - Kiovig
  - Panzyga
  - Iqymune
  - Gammaplex
2. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):
  - Berinert (Human C1-esterase inhibitor)
  - Cinryze (Human C1-esterase inhibitor)
  - Firazyr (Icatibant injection)
  - Orladeyo (Berotralstat)
  - Ruconest (Recombinant Human C1-esterase inhibitor)
  - Takhzyro (Lanadelumab)
3. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1)
4. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:
  - Danazol
  - Oxandralone
  - Stanozolol

**Response:**

Hywel Dda University Health Board (UHB) is applying an exemption under Section 40(2) of the Freedom of Information Act 2000 (FOIA) for part of question 1 and for the whole of questions 3 and 4, due to the low number of cases (5 and under) as there is a potential risk of identifying individuals if this was disclosed.

This information is protected by the Data Protection Act 2018/General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

1. Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of patients that have been treated with the Immunoglobulin treatments provided, during the period 1 September 2021 to 28 February 2022.

Treatment	Number
Cutaquig	0
Cuvitru	0
Gammanorm	0
Hizentra	0
Hyqvia	0
Subgam	*
Privigen	40
Octagam	*
Intratect	*
Gamunex	*
Kiovig	0
Panzyga	0
Iqymune	14
Gammaplex	0
Total	64

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients and a Section 40(2) exemption has been applied.

2. The UHB confirms that no patients have received the treatments provided, during the period 1 September 2021 to 28 February 2022.
3. & 4. A Section 40(2) exemption has been applied, please see explanation above.